Media Articles Related to Relenza (Zanamivir)
Why Is Influenza So Difficult to Prevent and Treat?
Source: Medscape Family Medicine Headlines [2015.01.23]
Drs Andrew Pavia and Greg Poland answer questions about why this season's flu vaccine was less effective, why the public is resistant to being vaccinated, and how antivirals should really be used.
Medscape Family Medicine
Source: MedicineNet Bioterrorism Specialty [2015.01.15]
Title: Flu (Influenza)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/15/2015 12:00:00 AM
Brain protein found to aid influenza recovery
Source: Respiratory / Asthma News From Medical News Today [2015.01.14]
Washington State University Spokane scientists have found a brain protein that boosts the healing power of sleep and speeds an animal's recovery from the flu.
Potential for inhalable vaccines for influenza, pneumonia, with new approach
Source: Respiratory / Asthma News From Medical News Today [2015.01.09]
Researchers at the University of North Carolina at Chapel Hill and North Carolina State University have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows...
New candidate vaccine against risky avian influenza
Source: Bird Flu / Avian Flu News From Medical News Today [2014.11.26]
The avian influenza (bird flu) virus of the H5N1 subtype continues to infect people, especially in South-Eastern Asia.
Published Studies Related to Relenza (Zanamivir)
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. [2010.11.02]
CONCLUSIONS: In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. Despite the theoretical potential for the reduction of the emergence of antiviral resistance, the lower effectiveness of this combination calls for caution in its use in clinical practice. TRIAL REGISTRATION: www.ClinicalTrials.govNCT00799760.
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. [2008.01]
OBJECTIVE: To compare the effectiveness of zanamivir with oseltamivir for influenza A and B... CONCLUSION: Zanamivir therapy is more effective than oseltamivir for the treatment of influenza B infection.
Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.08]
Background: Influenza can cause significant morbidity and mortality in subjects at high risk for complications, including the elderly (age >/=65 years) and those with chronic respiratory, cardiovascular, or metabolic conditions...
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. [2003.06]
Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there is no specific antiviral treatment with proven efficacy. We conducted a double-blind, randomized, placebo-controlled trial to assess the tolerability and efficacy of nebulized zanamivir (16 mg four times a day) in combination with rimantadine compared to rimantadine with nebulized saline for treating influenza in adults hospitalized with influenza...
Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. 
A randomized, double-blind, placebo-controlled, parallel-group trial performed at 5 residential units of the Finnish Defence Forces was conducted to assess the antiviral activity, efficacy and safety of inhaled zanamivir for the treatment of naturally acquired influenza... Zanamivir rapidly reduced viral load following the start of therapy compared with placebo and was well tolerated.
Clinical Trials Related to Relenza (Zanamivir)
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir [Not yet recruiting]
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly
emerging influenza A virus, antiviral drugs are seen as essential requirements for control of
initial influenza outbreaks. Two antivirals are available for the treatment oseltamivir and
zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared
opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will
be investigated by a randomized, placebo controlled, double blind study in France, during the
next winter season . This study will be conducted in 300 centres of primary care with 900
adults with a virologically suspected influenza A infection. Individuals will be randomized
to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo
+zanamivir. The primary judgment criteria will be the proportion of patients with negative RT
PCR negative in nasal secretions at Day 2.
A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects [Terminated]
This study is a 4 period study to see if there is any interaction between Orally-Administered
Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults [Recruiting]
Due in part to widespread availability of oseltamivir and clinical experience using
oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become
resistant to it. Other reliable methods of treating H5N1 must be identified in case of a
pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The
primary purpose of this study is to evaluate the interaction between oral oseltamivir and
intravenous zanamivir administered as either a continuous or intermittent infusion in
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection [Recruiting]
The outbreak of respiratory illnesses in Mexico that began in March 2009 was caused by a
swine origin influenza A (H1N1) virus (S-OIV) that had not been recognized previously in
pigs or humans. As of 17 May 2009, 39 countries have officially reported 8480 cases of
influenza A (H1N1) infection.
The H1N1 influenza A virus appears sensitive to oseltamivir and zanamivir in vitro, but
resistant to amantadine and rimantadine. This study is to test the oseltamivir, zanamivir
and placebo arms as the first line treatment for human swine influenza infection. Through
the study, the investigators may have better understanding about the clinical and,
biochemical, virological profiles of oseltamivir/zanamivir on the H1N1 virus, and optimizing
the treatment strategy among the Chinese population.
Zanamivir Versus Trivalent Split Virus Influenza Vaccine [Not yet recruiting]
This unblinded pilot study is intended to assess the feasibility of a larger double-blind,
randomized control trial. For the larger trial the investigators are interested in
understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors
for influenza infection in healthy adults, and in assessing the safety and tolerability of
seasonal antiviral prophylaxis in healthcare workers.
The pilot study will be assessing the rate of infection with influenza and the rate of
adherence to long-term zanamivir in 60 healthy volunteers.
Reports of Suspected Relenza (Zanamivir) Side Effects
Abnormal Behaviour (40),
Loss of Consciousness (8),
Depressed Level of Consciousness (8),
Pyrexia (7), more >>